Jessica Menis
Overview
Explore the profile of Jessica Menis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mountzios G, Saw S, Hendriks L, Menis J, Cascone T, Arrieta O, et al.
Cancer Treat Rev
. 2025 Feb;
134:102902.
PMID: 39978083
The advent of antibody-drug conjugates (ADCs) aims to transform the therapeutic landscape of advanced non-small cell lung cancer (NSCLC). The distinctive architecture of ADCs enables the targeted delivery of highly...
2.
Remon J, Bortolot M, Bironzo P, Cortiula F, Menis J, Brandao M, et al.
J Clin Oncol
. 2025 Jan;
43(9):1148-1156.
PMID: 39836933
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, with ICBs administered at flat...
3.
Cortiula F, Desai A, Menis J, Filippi A
Front Oncol
. 2024 Nov;
14:1503613.
PMID: 39558955
No abstract available.
4.
Rossi A, Zacchi F, Reni A, Rota M, Palmerio S, Menis J, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519290
Epigenetic dysregulation has long been recognized as a significant contributor to tumorigenesis and tumor maintenance, impacting all recognized cancer hallmarks. Although some epigenetic drugs have received regulatory approval for certain...
5.
Bertolaccini L, Tralongo A, Del Re M, Facchinetti F, Ferrara R, Franchina T, et al.
Lung Cancer
. 2024 Oct;
197:107990.
PMID: 39461280
While recent randomized controlled trials (RCT) have suggested superior overall survival (OS) outcomes with segmentectomy over lobectomy, questions remain regarding the comparability of these surgical procedures for treating early-stage non-small...
6.
Trestini I, Belluomini L, Dodi A, Sposito M, Caldart A, Kadrija D, et al.
J Cachexia Sarcopenia Muscle
. 2024 Oct;
15(6):2349-2360.
PMID: 39439222
Background: While immune checkpoint inhibitors (ICIs) are increasingly reshaping the therapeutic landscape of non-small-cell lung cancer (NSCLC), only a limited proportion of patients achieve a relevant and long-lasting benefit with...
7.
Sposito M, Belluomini L, Nocini R, Insolda J, Scaglione I, Menis J, et al.
Front Oncol
. 2024 Jul;
14:1436588.
PMID: 39045557
Introduction: To date, for all non-small cell lung cancer (NSCLC) cases, it is recommended to test for driver alterations to identify actionable therapeutic targets. In this light, comprehensive genomic profiling...
8.
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, et al.
Clin Lung Cancer
. 2023 Dec;
25(3):233-243.e8.
PMID: 38105153
Introduction: The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung cancer (NSCLC). We aimed to assess...
9.
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort
Borghetti P, Facheris G, Ciammella P, Galaverni M, Granello L, Scotti V, et al.
Clin Lung Cancer
. 2023 Dec;
25(2):151-158.
PMID: 38052684
Aims: SCLC is the most aggressive lung cancer histology with a 5-year OS <10%. At the diagnosis, almost two-thirds of the SCLC an Extended Disease presentation. Two randomized studies (CASPIAN...
10.
Remon J, Saw S, Cortiula F, Singh P, Menis J, Mountzios G, et al.
J Thorac Oncol
. 2023 Oct;
19(2):199-215.
PMID: 37783386
Treatment with 3 years of adjuvant osimertinib is considered a new standard in patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing EGFR mutation. This therapeutic...